Digital Media Net - Your Gateway To Digital media Creation. News and information on Digital Video, VR, Animation, Visual Effects, Mac Based media. Post Production, CAD, Sound and Music
VERO BEACH, Fla.–(BUSINESS WIRE)–Orchid Island Capital, Inc. (NYSE:ORC) (“Orchid” or the “Company”), a real estate investment trust (“REIT”), today announced that it will release results for the first quarter of 2022 following the close of trading on the New York Stock Exchange on Thursday, April 28, 2022.
Earnings Conference Call Details
An earnings conference call and live audio webcast will be hosted Friday, April 29, 2022, at 10:00 AM ET. The conference call may be accessed by dialing toll free (888) 510-2536. The conference ID is 8493186. A live audio webcast of the conference call can be accessed via the investor relations section of the Company’s website at www.orchidislandcapital.com, and an audio archive of the webcast will be available until May 27, 2022
About Orchid Island Capital, Inc.
Orchid Island Capital, Inc. is a specialty finance company that invests on a leveraged basis in Agency RMBS. Our investment strategy focuses on, and our portfolio consists of, two categories of Agency RMBS: (i) traditional pass-through Agency RMBS, such as mortgage pass-through certificates issued by Fannie Mae, Freddie Mac or Ginnie Mae and CMOS, and (ii) structured Agency RMBS. Orchid is managed by Bimini Advisors, LLC, a registered investment adviser with the Securities and Exchange Commission.
Contacts
Orchid Island Capital, Inc.
Robert E. Cauley, 772-231-1400
Chairman and Chief Executive Officer
www.orchidislandcapital.com
SOLANA BEACH, Calif.--(BUSINESS WIRE)--Macnica Americas today announced the appointment of Nestor Amaya as Vice President…
Every year, millions of Americans who miss their tax filing deadlines assume the IRS is…
Genius Sports has deployed its cutting-edge data and AI platform GeniusIQ in every Liga MX…
Starting June 4, My Best Buy Plus™ and My Best Buy Total™ members will automatically…
New platform combines 17 years of proprietary compliance data with direct access to credentialed experts,…
Translational Data Inform a Scalable, Noninvasive Test Designed to Identify Treatment-Eligible Patients and Enable Longitudinal…